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Background: Noninvasive ventilation (NIV) improves gas-exchange and symptoms in selected 
chronic obstructive pulmonary disease (COPD) patients with hypercapnic respiratory failure. We 
hypothesized NIV reverses respiratory failure by one or all of increased ventilatory response to 
carbon-dioxide, reduced respiratory muscle fatigue, or improved pulmonary mechanics.
Methods: Nineteen stable COPD patients (forced expiratory volume in one second 35% pre-
dicted) were studied at baseline (D0), 5–8 days (D5) and 3 months (3M) after starting NIV.
Results: Ventilator use was 6.2 (3.7) hours per night at D5 and 3.4 (1.6) at 3M (p = 0.12). 
Mean (SD) daytime arterial carbon-dioxide tension (PaCO2) was reduced from 7.4 (1.2) kPa 
to 7.0 (1.1) kPa at D5 and 6.5 (1.1) kPa at 3M (p = 0.001). Total lung capacity decreased from 
107 (28) % predicted to 103 (28) at D5 and 103 (27) % predicted at 3M (p = 0.035). At D5 
there was an increase in the hypercapnic ventilatory response and some volitional measures 
of inspiratory and expiratory muscle strength, but not isolated diaphragmatic strength whether 
assessed by volitional or nonvolitional methods.
Conclusion: These ﬁ  ndings suggest decreased gas trapping and increased ventilatory sensitivity 
to CO2 are the principal mechanism underlying improvements in gas-exchange in patients 
with COPD following NIV. Changes in some volitional but not nonvolitional muscle strength 
measures may reﬂ  ect improved patient effort.
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Introduction
In selected COPD patients, noninvasive ventilation (NIV) plus long-term oxygen 
therapy (LTOT) improves arterial carbon-dioxide tension (PaCO2), sleep-time and 
efﬁ  ciency and health related quality of life compared to LTOT alone (Meecham-Jones 
et al 1995; Clini et al 2002). Despite these observations, and widespread NIV use in 
hypercapnic restrictive thoracic disease (Kerby et al 1987; Carroll and Branthwaite 
1988; Ellis et al 1988; Leger et al 1994), its use in COPD remains controversial (Hill 
2000; Rossi 2000). This is partly because in previous studies less than half of COPD 
patients continued to use NIV at 3 (Leger et al 1994) and 5 years (Simonds and Elliott 
1995). It may also reﬂ  ect the poor prognosis of end-stage COPD, with 5 and 10 year 
survival rates of 30 and 8% respectively (Robert et al 1983).
Improved understanding of how NIV delivered at night improves day-time 
gas-exchange and symptoms may aid patient selection and NIV implementation. 
In a previous study of patients with restrictive thoracic disease (Nickol et al 2005) 
we demonstrated NIV increases ventilatory sensitivity to carbon-dioxide, but is not 
associated with increased respiratory muscle strength that may be brought about by relief 
of fatigued respiratory muscles, and it does not improve pulmonary mechanics.
This study aims to investigate these three potential mechanisms of action of NIV, 
and compare COPD and restrictive thoracic disease patients.International Journal of COPD 2008:3(3) 454
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Methods
This prospective, observational study was approved by the 
hospital’s ethics committee, and written informed consent 
obtained. Consecutive stable COPD patients with symptomatic 
hypercapnic respiratory failure (for example nocturnal awak-
ening, daytime somnolence and morning headaches), admit-
ted to hospital for elective initiation of nocturnal NIV were 
invited to participate. Ventilators were chosen according to 
availability and generally set up in pressure-control mode 
(mean [SD] inspiratory pressure 23.5 [4.7] and positive expi-
ratory pressure of 5–6 cm H2O in 10 patients). The following 
ventilators were used: NIPPY-1 (n = 4; B&D Electromedical, 
UK), VPAP-II ST (n = 10; ResMed, UK) and BREAS-PV 
‘102’ (n = 1), ‘401’ (n = 1) and ‘403’ (n = 2; BREAS Medical, 
Sweden), BiPAP-Harmony (n = 1) and BromptonPac volume 
control (n = 1; Brompton Hospital, London). Patients were 
studied at baseline (D0), 5–8 days (D5) and three months after 
commencing NIV (3M), including clinical review, subjective 
sleepiness using the Epworth sleepiness score (ESS), daytime 
arterial blood gases (after 20 minutes rest seated breathing 
air), overnight pulse oximetry (pulse oximeter 200–E, Nellcor, 
USA) and transcutaneous CO2 pressure (PtcCO2; Radiometer 
A/S, Denmark). Ventilator pressures were titrated upwards 
as tolerated to improve nocturnal hypoventilation, reﬂ  ected 
by peak nocturnal PtcCO2 and daytime PaCO2. Besides lung 
function all tests were performed at the same time of day for 
each patient starting at 10 am or 2 pm, and took approximately 
2½ hours. All data except compliance were acquired, stored 
and analyzed on a Macintosh computer using customized 
software (LabviewTM; National Instruments, USA). Patients 
refrained from caffeine for at least two hours before the 
study. The following tests were carried out with gastric and 
esophageal balloon catheters in situ.
The hypercapnic ventilatory response (HCVR) was 
determined using a re-breathing technique (Read 1967). 
Patients breathed in a closed circuit from a 6L anesthetic 
bag, ﬁ  lled with 5% CO2, balance oxygen for four minutes, 
whilst their end-tidal CO2 and ventilation were measured 
breath by breath. Two HCVR runs were performed, separated 
by at least 30 minutes, and the mean of the two runs used. The 
following measures of respiratory muscle strength were 
determined as described previously; (Polkey et al 1995) sniff 
nasal inspiratory pressure (SNIP), sniff esophageal pressure 
(Sniff Poes), maximum inspiratory and expiratory mouth 
pressure (maximum inspiratory mouth pressure [PiMax] 
and maximum expiratory mouth pressure [PeMax]), cough 
gastric pressure (Pga), sniff transdiaphragmatic pressure 
(Sniff Pdi) and twitch transdiaphragmatic pressure (TwPdi), 
assessed using bilateral anterolateral phrenic nerve magnetic 
stimulation. Full pulmonary function was measured at D0 
and 3M and lung volumes alone at D5. Static lung and chest 
wall compliance were determined using a quasistatic tech-
nique and standard lung function testing equipment (Jaegar 
Compact Body, Viasys Systems Ltd, UK).
Data analysis
Statistical analysis was carried out using SPSS V10 (SPSS 
Inc, Chicago, IL), and values expressed as mean (SD). Statis-
tical signiﬁ  cance was deﬁ  ned as p  0.05. Paired t-tests and 
one-way repeated measures of analysis of variance were used 
to compare variables measured on two and three occasions 
respectively, and linear regression analysis for examining the 
relationship between changes in variables. Mann Whitney-U 
test was used for between group comparisons. All data was 
normally distributed (Kolmogorov-Smirnov test).
Results
Patient characteristics
Twenty-four COPD patients were invited to participate. 
Four declined, and one with severe disease (forced expira-
tory volume in one second [FEV1] 15% predicted) could not 
continue after baseline studies due to dyspnea. Baseline data 
of the remaining 19 patients are shown in Table 1. Eighteen 
underwent repeat studies at D5 (one was unable to attend) 
and 16 at 3M (two died; one had a stroke).
Tobacco smoking was the etiology of COPD in 17/19 
patients; two had ﬁ  xed airﬂ  ow limitation due to longstanding 
asthma. Two patients were transferred directly from other 
hospitals, one following an acute exacerbation 6 weeks pre-
viously, and one following a progressive decline associated 
worsening cor pulmonale. The other 17 patients were admit-
ted electively from home, and were stable over the preceding 
three months. All patients had co-morbidities; 13 were clini-
cally obese (body mass index [BMI] 30 kg/m2), three were 
overweight (BMI 25–29.9 kg/m2), and only three were slim 
(BMI 25 kg/m2). Nine out of 19 gave a history of snoring 
and daytime somnolence suggesting COPD/obstructive sleep 
apnea (OSA) cross-over syndrome. In line with standard UK 
practice we did not attempt to clarify whether obstruction 
or hypoventilation predominated. Eleven had stable cardio-
vascular disease, three had type II diabetes mellitus, and two 
had coexistent restrictive lung disease (bilateral diaphragm 
weakness and kyphoscoliosis) judged to be minor in com-
parison to COPD on the basis of lung function tests. Patients 
with a history suggesting COPD/OSA cross-over syndrome 
were heavier with smaller lung volumes. Two patients were International Journal of COPD 2008:3(3) 455
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already on LTOT and seven were started on it with NIV as 
oxygen had not previously been tolerated due to excessive 
hypercapnia. One patient had oxygen supplementation at 
night only, and another had it as required during the day.
Use and efﬁ  cacy of NIV
Ventilator use information where available, was highly 
variable, with numerically greater adherence at D5 than 3M 
(not signiﬁ  cant, p = 0.12). 12/16 patients used NIV for more 
than 4 hours at D5, but only 2/10 at 3M. 8 patients with use 
available at D5 and 3M used NIV 6.2 (3.7) hours per night 
at D5 and 3.4 (1.6) at 3M. Use was not greater in those with 
OSA compared to those without at D5 (7.3 [4.2] hours per 
night versus 6.5 [2.4], p = 0.87) or at 3M (4.9 [2.4] versus 
2.7 [0.5], p = 0.15).
There was a progressive fall in PaCO2, from 7.4 (1.2) kPa at 
D0, 7.0 (1.1) kPa at D5 and 6.5 (1.1) kPa at 3M. There was also 
a fall in arterial bicarbonate and ESS, and rise in arterial oxygen 
tension (PaO2) (Figure 1). Peak nocturnal transcutaneous CO2 
was measured at D0, D5, and 3M in 15, 17, and 14 patients, 
respectively. It fell from 13.2 (4.5) at baseline to 9.3 (3.1) at 
D5 and 8.4 (1.6) kPa at 3M (p = 0.001). There was a signiﬁ  cant 
relationship between the fall in PaCO2 and fall in bicarbonate 
at D5 (p  0.001; r2 = 0.72) and a trend towards a relationship 
at 3M (p = 0.09; r2 = 0.19). Hydrogen ion concentration did 
not change signiﬁ  cantly (p = 0.42), at 40.2 (2.5) mM/L at D0, 
39.0 (2.2) mM/L at D5 and 39.0 (5.0) mM/L at 3M.
Ventilatory response to carbon-dioxide
18/19 patients carried out HCVR testing at baseline and 
on at least one further occasion. The mean (SD) HCVR 
was 4.1 (3.2) l/min/kPa at baseline, 5.1 (3.5) l/min/kPa at 
5D and 5.0 (3.4) l/min/kPa at 3M (Figure 2). This increase 
was not signiﬁ  cant overall from D0 to D5 to 3M (p = 0.23), 
Table 1 Mean (SD) baseline characteristics (n = 19) for all patients with COPD, and subdivisions without and with clinical evidence of OSA
Characteristics All patients (n = 19) No OSA (n = 10) OSA (n = 9) No OSA cf OSA (p value)
Anthropometrics
Sex, M: F 11:08 6:4 5:4 –
Age (years) 62     (12) 59 (15) 65 (6) 0.60
Pack years (years) 48     (29) 44 (26) 52 (32) 0.72
BMI (kg/ m2) 35 (8) 30 (6) 39 (8) 0.019*
PaO2 (kPa) 7.3 (1.0) 7.4 (1.2) 7.3 (0.8) 0.66
PaCO2 (kPa) 7.4 (1.2) 7.6 (1.6) 7.1 (0.7) 0.60
Peak noct PtcCO2 (kPa) 13.2 (4.5) 13.9 (5.0) 12.2 (3.8) 0.78
ESS (out of 24) 13 (6) 14 (4) 12.1 (6.7) 0.44
Drive
HCVR (l/min/ kPa) 4.1 (3.2) 4.5 (4.1) 3.6 (2.0) 0.80
Muscle strength
PiMax (cmH2O) 48 (15) 51 (13) 44 (16) 0.36
Poes (cmH2O) 64 (12) 64 (13) 64 (12) 0.96
PeMax (cmH2O) 91 (39) 82 (38) 101 (41) 0.32
Sniff Pdi (cmH2O) 76 (23) 68 (19) 84 (26) 0.38
TwPdi (cmH2O) 7 (5) 5 (4) 8 (6) 0.57
Lung function
FEV1 (% Predicted) 35 (16) 29 (13) 42 (16) 0.14
FEV1: FVC 43 (18) 39 (20) 47 (15) 0.37
TLC (% Predicted) 111 (25) 123 (19) 98 (24) 0.024*
FRC (% Predicted) 151 (36) 171 (30) 131 (31) 0.008*
RV (% Predicted) 193 (41) 221 (29) 166 (32) 0.003*
Static compliance
CLung (mls/ cmH2O) 110 (47) 112 (49) 107 (49) 0.73
CCW (mls/ cmH2O) 128 (41) 142 (37) 114 (44) 0.24
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; ESS, Epworth sleepiness score; FEV1, forced expiratory volume in 1 second; FRC, 
functional residual capacity; HCVR, hypercapnic ventilatory response; OSA, obstructive sleep apnea; PaCO2, arterial carbon-dioxide tension; PaO2, arterial oxygen tension; 
PeMax, maximum expiratory mouth pressure; PiMax, maximum inspiratory mouth pressure; PtcCO2, transcutaneous CO2 pressure; SD, standard deviation; Sniff Pdi, sniff 
transdiaphragmatic pressure; TwPdi, twitch transdiaphragmatic pressure.International Journal of COPD 2008:3(3) 456
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Figure 1 Effect of NIV on arterial blood gases and ESS. Mean (SEM) PaCO2, PaO2, arterial bicarbonate and ESS at D0, D5 and 3M are shown. There was a signiﬁ  cant fall in 
PaCO2 (p = 0.001), bicarbonate (p = 0.011) and ESS (p = 0.001), and rise in PaO2 (p = 0.004).
Abbreviations: ESS, Epworth sleepiness score; NIV, noninvasive ventilation; SEM, standard error of mean; PaCO2, arterial carbon-dioxide tension; PaO2, arterial oxygen tension.
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however was signiﬁ  cant from baseline to 5D (p = 0.011). 
HCVR is dependent upon FEV1 (signiﬁ  cant linear regression, 
p = 0.001; r2 = 0.48), however there were no changes in FEV1. 
There was no signiﬁ  cant change in intercept, or ventilation 
at a PetCO2 of 8 kPa.
Respiratory muscle strength
All 19 patients carried out noninvasive tests of muscle 
strength, 15 carried out invasive tests at baseline and D5, 
and 11 on all three occasions. Overall there were no sig-
niﬁ  cant changes in strength, and only a trend towards an 
increase in PeMax (p = 0.06, Figure 3). Comparing baseline 
and D5, there were signiﬁ  cant increases in two measures of 
inspiratory muscle strength (SNIP, p = 0.025 and PiMax, 
p = 0.027) and a trend towards an increase in the third 
measure (Sniff Poes, p = 0.071). One measure of expiratory 
muscle strength increased (PeMax, p  =  0.033) however 
another did not (Pga, p = 0.44). There were no changes 
in volitional trans-diaphragmatic pressure (Sniff Pdi, 
p  =  0.75) or nonvolitional transdiaphragmatic pressure 
(TwPdi 7 [5] on each occasion, p = 0.93). Changes in muscle 
strength occurred independent of lung volumes; there was no 
change in FRC, and no correlation between the increase in 
PeMax and decrease in total lung capacity (TLC) (r2 = 0.14; 
p = 0.17 at D5 and r2 = 0.19; p = 0.10 at 3M).
Pulmonary mechanics
Thirteen patients carried out lung volume measurements on 
all 3 occasions, and 16 patients at baseline and D5. There 
was a signiﬁ  cant fall in TLC from 6.04 (1.65) L at baseline 
to 5.82 (1.65) L at D5 and 5.86 (1.66) L at 3M (p = 0.035). 
There was a trend towards reduction of residual volume (RV) 
(p = 0.07) and no change in functional residual capacity 
(FRC) (p = 0.11), Figure 4, left panel. There was a signiﬁ  cant 
decrease in gas trapping, (TLC minus alveolar volume) from 
baseline to three months (p = 0.04, Figure 4, right panel). 
There were no consistent changes in spirometry or carbon-
monoxide transfer factor. There was a signiﬁ  cant change in 
static chest wall compliance (p = 0.01), with an increase at 
D5, and fall back to below baseline at 3M, and no change in 
static lung compliance (p = 0.13).
Subset analysis
Omitting 2 patients who were transferred from other hos-
pitals did not change the main ﬁ  ndings of the study. Both 
patients with and without OSA/cross-over syndrome had 
signiﬁ  cant decreases in PaCO2 post-NIV, however only 
those with OSA/cross-over syndrome had an overall 
increase in PaO2 (p = 0.001 versus 0.23) and reduction in 
ESS (p = 0.004 versus 0.08), and increase in HCVR at D5 
(p = 0.019 versus 0.17).
Dose response
In contrast to patients with restrictive disease, there was no 
linear regression between changes in PaCO2 or ESS and 
hours of use, however patients using NIV for more than 4 
hours per night tended to have no change or an increase in 
HCVR and decrease in TLC, whilst those using it for less 
than 4 hours had no consistent changes (Figure 5, top panels). 
There was also a tendency for a fall in PaCO2 to be associated 
with an increase in HCVR and decrease in TLC (Figure 5, 
bottom panels). This was signiﬁ  cant only at 3M for HCVR 
(r2 = 0.35; p = 0.02).
Discussion
This study examines three hypotheses by which gas-exchange 
may improve following NIV in COPD patients with symp-
tomatic hypercapnic respiratory failure: increased ventilatory 
sensitivity to CO2, increased respiratory muscle strength, and 
improved pulmonary mechanics. The ﬁ  ndings support the ﬁ  rst 
and third mechanisms, with an increase in HCVR, at least at 
D5, and decrease in TLC. This contrasts with our previous data 
in patients with restrictive disease, where increased HCVR 
alone was shown to be associated with NIV use.
Figure 2 Effect of NIV on HCVR Mean (SEM) HCVR at D0, D5 and 3M is shown.  There 
was no overall signiﬁ  cant increase in HCVR (p = 0.23), however there was a signiﬁ  cant 
increase in HCVR from baseline to 5D when NIV use was good (p = 0.009).
Abbreviations: HCVR, hypercapnic ventilatory response; NIV, noninvasive ventilation; 
SEM, standard error of mean.
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Critique of the method
Although our data have the merit of reﬂ  ecting the ‘real 
world’, we acknowledge that the ﬁ  ndings of our study are 
limited by the relatively small sample size, mixed nature 
of the population studied, poor average adherence rates 
and lack of a control group. It would have been preferable 
for patients to undergo a standardized run-in period for 
medical optimization before commencing NIV, and to have 
a randomized control group without NIV. Despite NIV in 
COPD not being standard treatment for ‘all-comers’, we did 
not consider it practical to delay treatment in this cohort, or 
admit patients to hospital without offering NIV. They had 
been referred by external respiratory specialists because of 
marked symptoms of hypoventilation, or because they were 
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Figure 4 Effect of NIV on lung volumes (left panel) and gas trapping measured as TLC – alveolar volume, (right panel). Mean (SEM) values at D0, D5, and 3M are shown. The 
fall in TLC and gas trapping were signiﬁ  cant (p = 0.035 and 0.04, respectively).
Abbreviations: NIV, noninvasive ventilation; SEM, standard error of mean. TLC, total lung capacity.
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Figure 3 Effect of NIV on inspiratory, expiratory and diaphragmatic respiratory muscle strength. Mean (SEM) values at D0, D5, and 3M are shown.
Abbreviations: NIV, noninvasive ventilation; SEM, standard error of mean; Sniff Poes, sniff esophageal pressure; PiMax, maximum inspiratory pressure; SNIP, sniff nasal pressure; 
PeMax, maximum expiratory pressure; Pga, cough gastric pressure; Sniff Pdi, sniff transdiaphragmatic pressure; TwPdi, twitch transdiaphragmatic pressure.
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Figure 5 Changes in the hypercapnic ventilatory response (left panels) and TLC (right panels) versus mean hours of NIV use per night (top panels) and change in PaCO2 
(bottom panels). Closed circles denote data at D5 and open circles at 3M. Dotted lines in the top panels indicate 4 hours of use per night.
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unable to tolerate LTOT without ventilatory support (n = 7). 
Nevertheless in the light of our main conclusion we now 
believe a prospective randomized controlled trial would be 
appropriate given less good NIV adherence at 3 months.
Signiﬁ  cance of f  indings
Use and efﬁ  cacy of NIV
Daytime arterial blood gases and subjective sleepiness 
improved signiﬁ  cantly. In contrast to most previous studies, 
we did not attempt to dissect the relative contributions of 
OSA and COPD to hypoventilation since this is not usual in 
the UK. As in previous studies of COPD, (Leger et al 1994; 
Simonds and Elliott 1995) adherence to NIV decreased with 
time from 6.2 (3.7) to 3.4 (1.6) hours per night at D5 and 
3M, respectively, compared with 6.7 (1.9) to 4.2. (2.6) hours 
per night in patients with restrictive lung disease (Nickol 
et al 2005). Reasons for greater early use in our studies may 
include greater patient motivation due to high expectations 
of a new treatment, intensive support from the multidisci-
plinary team, and nurse led decisions regarding NIV start and 
stop times. Speciﬁ  c to COPD may be excess dyspnea and 
sputum production leading to poor interface tolerance, with 
little amelioration of these symptoms by NIV. In contrast, in 
restrictive disease, symptoms of hypoventilation predominate 
and NIV is usually effective in relieving these. Furthermore 
there is greater technical difﬁ  culty perfectly adjusting the ven-
tilator for patient comfort in COPD due to intrinsic positive 
end-expiratory pressure and dynamic hyperinﬂ  ation leading 
to increased work of breathing triggering the ventilator, and 
the requirement of a prolonged expiratory phase. Of note in 
our study patients with lower adherence to NIV reported more 
technical problem such as air leaks (n = 1) and synchroniza-
tion difﬁ  culty (n = 2). 
Increased ventilatory sensitivity to CO2
At early follow-up increased HCVR supports the ﬁ  rst hypoth-
esis. At 3M this became nonsigniﬁ  cant, perhaps due to reduced 
NIV use. We speculate that increased HCVR enables a more 
appropriate increase in ventilation to occur in response to 
transient increases in PaCO2, so diminishing hypercapnia. 
Increased HCVR in turn is likely to be due to decreased PaCO2, 
either directly (Gibson 2006), or indirectly through decreased 
renal retention of bicarbonate. Increased bicarbonate reduces 
acid buffering capacity, resetting the chemoreceptors so they 
respond at lower PCO2 levels. An additional mechanism that may 
have contributed to the increase in HCVR is sleep consolidation. 
For example, use of CPAP (Moura et al 2001) or tracheostomy 
(Guilleminault and Cummiskey 1982) in OSA has been shown to 
increase HCVR, at least in hypercapnic patients (Berthon-Jones 
and Sullivan 1987). Only one previous study has examined 
HCVR post-NIV in COPD (Elliott et al 1991), and similarly then 
found no change in HCVR at 3M. They did, however, observed 
a signiﬁ  cant correlation between decreased PaCO2 and increased 
ventilation at a PetCO2 of 8 kPa. We found a signiﬁ  cant correla-
tion between the fall in PaCO2 and increase in HCVR at 3M, but 
not with the increase in ventilation at a PaCO2 of 8 kPa.
At 3M blood gases continued to improve despite less 
NIV use and no further change in HCVR. This may be due 
to another mechanism, such as progressive optimization of 
lung volumes. Alternatively increased HCVR may facilitate 
escape from the downwards spiral of ventilatory failure. There 
may be restoration of imbalance between high ventilatory 
load (increased airways resistance, positive end-expiratory 
pressure [PEEP], and dynamic hyperinﬂ  ation), reduced 
respiratory muscle strength (functionally disadvantaged 
ﬂ  attened diaphragm), and blunted ventilatory drive (renal 
retention of bicarbonate). Improved gas exchange might 
then be maintained even with less NIV use. This is specula-
tive, and alternative causes of improvement to NIV must 
be considered such as intensive medical team exposure 
encouraging patients to adhere to medical therapy. Although 
patients appeared stable at study entry, it is possible that 
lack of baseline stability, with ‘regression to the mean’, 
may have contributed to the improvements seen during 
this study.
Improved muscle strength
The second hypothesis of relief of low frequency respiratory 
muscle fatigue is not supported. At D5 there were increases 
in two of three measures of inspiratory muscle strength 
and one of two measures of expiratory muscle strength. 
Some previous studies have also shown improvements 
in noninvasive measures of respiratory muscle strength 
(Marino and Braun 1982; Braun and Marino 1984; Zibrak 
et al 1986; Cropp and Dimarco 1987; Gutierrez et al 1988; 
Ambrosino et al 1990), but not others (Zibrak et al 1988; 
Elliott et al 1991; Lin 1996; Clini et al 2002). We found no 
change in the nonvolitional measure of muscle strength, 
TwPdi. A previous study, in which patients with poor NIV 
adherence were excluded from the analysis, has similarly 
shown no change in TwPdi (Schonhofer et al 2006). It is 
possible improved volitional measures observed in some 
studies simply reﬂ  ects improved patient effort. Changes 
in respiratory muscle endurance following NIV have not 
previously been assessed, and may be of greater relevance 
than strength.International Journal of COPD 2008:3(3) 461
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Decreased total lung volume
Total lung capacity and gas trapping (TLC minus alveolar 
volume) decreased significantly, supporting the third 
hypothesis. Decreases in FRC and RV failed to reach sig-
niﬁ  cance (p = 0.11 and 0.065), and there were no changes 
in spirometry, carbon-monoxide transfer or compliance. It 
may appear counter-intuitive that a positive pressure applied 
to the airway reduces TLC, however there are several plau-
sible mechanisms. Firstly NIV may splint open airways, so 
maintaining them above their closing volume throughout 
expiration aiding emptying. Secondly, NIV could change 
breathing pattern leading to slower, deeper breaths and 
reducing hyperinﬂ  ation, as has been shown in mechanically 
ventilated patients (Tuxen and Lane 1987) and in COPD 
patients during exercise (O'Donnell et al 2001). Lastly, NIV 
may reduce pulmonary engorgement, bronchial wall edema 
and surface tension forces, so improving small airway and 
alveolar patency.
Previous studies, so long as sufﬁ  cient inspiratory pres-
sures are used, have also shown reduced lung volumes 
(Budweiser et al 2005), with signiﬁ  cant correlations between 
reduced PaCO2 and PEEP (Diaz et al 2002) or gas-trapping 
(Elliott et al 1991). As in our study, the majority of previous 
studies have shown no changes in spirometry (Braun and 
Marino 1984; Zibrak et al 1986, 1988; Elliott et al 1991; Lin 
1996; Perrin et al 1997; Clini et al 2002; Schonhofer et al 
2006). The reason for the isolated increase in static chest 
wall compliance in our study at D5 and decrease at 3M is not 
clear. No previous studies have measured static compliance, 
and one previous study measured dynamic compliance, and 
found it to be unchanged (Elliott et al 1991).
Dose response
Although we have not demonstrated a ‘dose response’ of 
NIV, it is likely to underlie improved gas-exchange since 
those using it for 4 hours per night had no consistent 
changes in HCVR or TLC, whereas those using it for 4 
hours per night tended to have either no change or an increase. 
NIV ‘dose’ is likely to be more complex in obstructive than 
restrictive disease, with greater dependence on PEEP and 
patient-ventilator synchrony in addition to hours of use.
Conclusions
In conclusion, this study suggests improved gas-exchange 
and reduced sleepiness in symptomatic hypercapnic COPD 
patients initiated on NIV. It supports the hypothesis that 
improvements are brought about by optimization of pul-
monary mechanics with reduced gas-trapping and increased 
ventilatory sensitivity to CO2. We acknowledge that these 
mechanisms are only speculative, given that the fall in TLC 
was small, and that HCVR was not signiﬁ  cantly increased at 
3M. Other unmeasured factors such as increased adherence 
to drug therapy may have been relevant at 3M. Given that 
this is the case, then implementation of NIV should focus 
on appropriate setting of extrinsic PEEP and prolonged 
expiratory phase to maximize lung emptying. In addition, 
optimization of nocturnal CO2 control will aid chemorecep-
tors resetting to increase HCVR. The present data contrasts 
with those obtained from patients with restrictive lung 
disease, in which increased ventilatory sensitivity to CO2 
but not optimization of pulmonary mechanics is the key 
mechanism.
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